Clinical Trials on Tourette Syndrome

Total 33996 results

AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
Amphivena Therapeutics, Inc.

Completed

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome (MDS)

United States
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
Telik

Completed

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Completed

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Myelodysplastic Syndrome (MDS)

United States
Incyte Corporation

Terminated

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

MDS (Myelodysplastic Syndrome)

United States
Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Genzyme, a Sanofi Company

Terminated

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (RISE)

Myelodysplastic Syndrome (MDS)

Germany, United Kingdom, France, Netherlands
Heinrich-Heine University, Duesseldorf

Terminated

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (VALENA)

Myelodysplastic Syndrome MDS

Germany
Telik

Terminated

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Telik

Completed

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Seagen Inc.

Completed

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

Japan
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Recruiting

Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care (FISiM-NGS-MDS)

MDS (Myelodysplastic Syndrome)

Italy
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
Fujifilm Pharmaceuticals U.S.A., Inc.

Withdrawn

A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of ON 01910.Na in Patients With Myelodysplasia

Myelodysplastic Syndrome (MDS)

United States
Telik

Terminated

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Oncology Specialties, Alabama

Terminated

Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
University of Wisconsin, Madison

Terminated

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Compartment Syndrome of Leg

United States
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
Scripps Health
J. Craig Venter Institute

Completed

Biomarker Monitoring in TP53 Mutation Carriers

Li-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation Carrier

United States
Erasmus Medical Center

Enrolling by invitation

Long-term Pain Modulation by Intravenous Esketamine in CRPS (KetCRPS-2)

Complex Regional Pain Syndromes | CRPS (Complex Regional Pain Syndromes)

Netherlands
Institut fuer anwendungsorientierte Forschung und...
University Medical Center Goettingen

Completed

Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells

Myelodysplastic Syndromes (MDS) | Chromosmal Aberrations | Karyotype Evolution | Rare Abnormalities | Cytogenetic Monitoring

Germany
Larissa University Hospital

Recruiting

Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery

Dumping Syndrome | Gastric Surgery

Greece
Children's Hospital of Philadelphia
University of Pennsylvania

Recruiting

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Short Gut Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

High Risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome

United States
Jasper Therapeutics, Inc.

Recruiting

JSP191 (Briquilimab) in Subjects With LR-MDS

Lower-risk Myelodysplastic Syndrome

United States
University Health Network, Toronto
Zogenix, Inc.

Not yet recruiting

Fenfluramine for Adult Dravet Patients

Dravet Syndrome | Dravet Syndrome, Intractable

Canada
University of Texas Southwestern Medical Center
Children's Hospital of Philadelphia

Enrolling by invitation

Predicting Success With Fiber Food Introduction in Short Bowel Syndrome

Short Gut Syndrome

United States
Takeda

Completed

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Dravet Syndrome (DS)

China, Canada, France, Hungary, Poland, United States, Spain, Greece, Australia, Brazil, Serbia, Germany, Italy, Japan, Latvia, Netherlands, Ukraine, Russian Federation
Peter L Greenberg
Amgen

Completed

A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndromes (MDS) | Blood Cancer

United States
Uma Borate

Recruiting

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
University Hospital, Brest

Recruiting

Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes (SMD-RMB22)

Myelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)

France
Cyclacel Pharmaceuticals, Inc.

Suspended

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome(MDS)

United States
Northwestern University

Completed

Atrantil for Intestinal Bacterial Overgrowth

Irritable Bowel Syndrome | SIBO | Bacterial Overgrowth Syndrome

United States
U.S. Army Medical Research and Development Command

Unknown

The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients (NIRS)

Anterior Tibial Compartment Syndrome

United States
Vern C. Juel, M.D.

No longer available

Treatment Use of 3,4-Diaminopyridine

Myasthenic Syndromes, Congenital

United States
Ricardo Maselli
Catalyst Pharmaceuticals, Inc.

No longer available

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia

Congenital Myasthenic Syndrome

United States
Santa Casa da Misericordia do Rio de Janeiro Hospital

Unknown

Trial of Acupuncture in the Treatment of Fibromyalgia

Fibromyalgia | Myofascial Pain Syndrome, Diffuse | Diffuse Myofascial Pain Syndrome | Fibromyalgia-Fibromyositis Syndrome | Fibromyositis-Fibromyalgia Syndrome

Brazil
Karolinska Institutet
Region Stockholm

Active, not recruiting

Internet-based Cognitive Behavioral Therapy for Chronic Tic Disorder and Tourette's Disorder: a Feasibility Trial (TICNET)

Tourette Syndrome | Chronic Tic Disorder

Sweden
Tasly Pharmaceuticals, Inc.

Completed

Phase III Study of 5LGr to Treat Tic Disorder (5LGr)

Tourette Syndrome | Tic Disorder | Chronic Tic Disorder
Fidia Farmaceutici s.p.a.

Recruiting

Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%

Dry Eye Syndrome (DES)

Italy

Clinical Trials on Tourette Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations